(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology

Aubin Moutal, Lindsey A. Chew, Xiaofang Yang, Yue Wang, Seul Ki Yeon, Edwin Telemi, Seeneen Meroueh, Ki Duk Park, Raghuraman Shrinivasan, Kerry B. Gilbraith, Chaoling Qu, Jennifer Y. Xie, Amol Patwardhan, Todd W. Vanderah, May Khanna, Frank Porreca, Rajesh Khanna

Research output: Research - peer-reviewArticle

  • 3 Citations

Abstract

Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca 2+ influx with a low micromolar IC 50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca 2+ currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.

LanguageEnglish (US)
Pages1448-1463
Number of pages16
JournalPain
Volume157
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Neuralgia
Sensory Receptor Cells
Postoperative Pain
Phosphorylation
Pharmacology
collapsin response mediator protein-2
lacosamide
Inhibition (Psychology)
Neurons
Hyperalgesia
Cyclin-Dependent Kinase 5
Menthol
Electrophysiology
Spinal Ganglia
Protein Transport
United States Food and Drug Administration
Calcium Channels
Reward
Chronic Pain
Anticonvulsants

Keywords

  • (S)-lacosamide
  • Calcium imaging
  • CaV2.2
  • Constellation pharmacology
  • CRMP2
  • Neuropathic pain
  • Postoperative pain

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. / Moutal, Aubin; Chew, Lindsey A.; Yang, Xiaofang; Wang, Yue; Yeon, Seul Ki; Telemi, Edwin; Meroueh, Seeneen; Park, Ki Duk; Shrinivasan, Raghuraman; Gilbraith, Kerry B.; Qu, Chaoling; Xie, Jennifer Y.; Patwardhan, Amol; Vanderah, Todd W.; Khanna, May; Porreca, Frank; Khanna, Rajesh.

In: Pain, Vol. 157, No. 7, 01.07.2016, p. 1448-1463.

Research output: Research - peer-reviewArticle

Moutal, Aubin ; Chew, Lindsey A. ; Yang, Xiaofang ; Wang, Yue ; Yeon, Seul Ki ; Telemi, Edwin ; Meroueh, Seeneen ; Park, Ki Duk ; Shrinivasan, Raghuraman ; Gilbraith, Kerry B. ; Qu, Chaoling ; Xie, Jennifer Y. ; Patwardhan, Amol ; Vanderah, Todd W. ; Khanna, May ; Porreca, Frank ; Khanna, Rajesh. / (S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. In: Pain. 2016 ; Vol. 157, No. 7. pp. 1448-1463
@article{bf110d4b0e84404a9c02db443bfe82e7,
title = "(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology",
abstract = "Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca 2+ influx with a low micromolar IC 50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca 2+ currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.",
keywords = "(S)-lacosamide, Calcium imaging, CaV2.2, Constellation pharmacology, CRMP2, Neuropathic pain, Postoperative pain",
author = "Aubin Moutal and Chew, {Lindsey A.} and Xiaofang Yang and Yue Wang and Yeon, {Seul Ki} and Edwin Telemi and Seeneen Meroueh and Park, {Ki Duk} and Raghuraman Shrinivasan and Gilbraith, {Kerry B.} and Chaoling Qu and Xie, {Jennifer Y.} and Amol Patwardhan and Vanderah, {Todd W.} and May Khanna and Frank Porreca and Rajesh Khanna",
year = "2016",
month = "7",
doi = "10.1097/j.pain.0000000000000555",
volume = "157",
pages = "1448--1463",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - (S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology

AU - Moutal,Aubin

AU - Chew,Lindsey A.

AU - Yang,Xiaofang

AU - Wang,Yue

AU - Yeon,Seul Ki

AU - Telemi,Edwin

AU - Meroueh,Seeneen

AU - Park,Ki Duk

AU - Shrinivasan,Raghuraman

AU - Gilbraith,Kerry B.

AU - Qu,Chaoling

AU - Xie,Jennifer Y.

AU - Patwardhan,Amol

AU - Vanderah,Todd W.

AU - Khanna,May

AU - Porreca,Frank

AU - Khanna,Rajesh

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca 2+ influx with a low micromolar IC 50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca 2+ currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.

AB - Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca 2+ influx with a low micromolar IC 50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca 2+ currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.

KW - (S)-lacosamide

KW - Calcium imaging

KW - CaV2.2

KW - Constellation pharmacology

KW - CRMP2

KW - Neuropathic pain

KW - Postoperative pain

UR - http://www.scopus.com/inward/record.url?scp=84976370483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976370483&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000000555

DO - 10.1097/j.pain.0000000000000555

M3 - Article

VL - 157

SP - 1448

EP - 1463

JO - Pain

T2 - Pain

JF - Pain

SN - 0304-3959

IS - 7

ER -